Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Although Novo was first to market with Wegovy and its sister ... The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027.

CVS’s decision directly threatens a sizable portion of Zepbound’s addressable market. The potential impact of CVS's formulary decision regarding Zepbound may be somewhat limited. Lilly ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide ... While the study primarily looked at the impact of the medications, experts agreed there ...

The entrance of more GLP-1 agonists into the market, especially generic ones, could eventually bring prices down. But until that happens, if you are interested in taking Ozempic, Zepbound or any ...